Eric Sachetta Acquires 27,304 Shares of Sensus Healthcare (NASDAQ:SRTS) Stock

Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Eric Sachetta acquired 27,304 shares of Sensus Healthcare stock in a transaction that occurred on Monday, August 31st. The shares were purchased at an average price of $3.54 per share, for a total transaction of $96,656.16. Following the completion of the purchase, the director directly owned 294,784 shares of the company’s stock, valued at $1,043,535.36. The trade was a 10.21% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Eric Sachetta also recently made the following trade(s):

• On Friday, August 28th, Eric Sachetta bought 37,537 shares of Sensus Healthcare stock. The shares were acquired at an average price of $3.44 per share, with a total value of $129,127.28.
• On Thursday, August 27th, Eric Sachetta bought 10,925 shares of Sensus Healthcare stock. The shares were acquired at an average cost of $3.18 per share, for a total transaction of $34,741.50.
• On Wednesday, August 26th, Eric Sachetta purchased 9,708 shares of Sensus Healthcare stock. The stock was acquired at an average price of $3.29 per share, for a total transaction of $31,939.32.
• On Monday, August 24th, Eric Sachetta purchased 34,697 shares of Sensus Healthcare stock. The stock was acquired at an average cost of $3.25 per share, with a total value of $112,765.25.

Sensus Healthcare Price Performance

Shares of NASDAQ:SRTS traded up $0.12 during trading on Monday, reaching $3.64. 102,018 shares of the company’s stock traded hands, compared to its average volume of 65,130. Sensus Healthcare, Inc. has a 12 month low of $2.66 and a 12 month high of $5.49. The company has a 50 day moving average of $3.05 and a 200-day moving average of $3.51. The stock has a market capitalization of $59.91 million, a P/E ratio of -3.87 and a beta of 1.10.

Sensus Healthcare (NASDAQ:SRTS) last issued its earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.41). Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%.The company had revenue of $2.29 million during the quarter, compared to analyst estimates of $4.60 million.

Analyst Ratings Changes

A number of research firms have issued reports on SRTS. Citigroup reissued a “buy” rating on shares of Sensus Healthcare in a research note on Friday, May 8th. Weiss Ratings cut Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Wall Street Zen downgraded Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Alliance Global Partners restated a “buy” rating on shares of Sensus Healthcare in a research report on Monday, August 17th. Finally, Lake Street Capital cut their target price on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.83.

Institutional Trading of Sensus Healthcare

A number of hedge funds and other institutional investors have recently made changes to their positions in SRTS. State Street Corp grew its stake in shares of Sensus Healthcare by 5.2% in the 4th quarter. State Street Corp now owns 69,252 shares of the company’s stock worth $276,000 after purchasing an additional 3,400 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Sensus Healthcare by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 153,917 shares of the company’s stock worth $730,000 after purchasing an additional 3,766 shares in the last quarter. Sachetta LLC lifted its stake in Sensus Healthcare by 6.8% during the fourth quarter. Sachetta LLC now owns 148,508 shares of the company’s stock valued at $591,000 after purchasing an additional 9,500 shares during the last quarter. EP Wealth Advisors LLC bought a new stake in Sensus Healthcare during the second quarter worth approximately $49,000. Finally, XTX Topco Ltd bought a new stake in Sensus Healthcare during the fourth quarter worth approximately $77,000. 25.30% of the stock is currently owned by institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.